Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
Methaq Mueen Al-kaabi(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Asmail Muftah(Nottingham University Hospitals NHS Trust), Alaa T. Alshareeda(King Abdulaziz Medical City), Eleanor Cornford(Nottingham University Hospitals NHS Trust), Stephen Chan(Heidelberg University), Ian O. Ellis(University of Nottingham), Dena Jerjees(Nottingham University Hospitals NHS Trust), Andrew R. Green(Nottingham Biomedical Research Centre), Nouf H. Alsubhi(King Abdulaziz University), Christopher C. Nolan(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 50
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639